WFA
REGN icon

Wedbush Fund Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Wedbush Fund Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35K Buy
+15
New +$10.2K ﹤0.01% 99

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Wedbush Fund Advisers's REGN Position: Q2 2026 in Review

Wedbush Fund Advisers opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 15 shares worth $9.35K. The stake represents ﹤0.01% of the portfolio and ranks #99 among its holdings.

1,310 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Wedbush Fund Advisers held 15 shares of Regeneron Pharmaceuticals worth $9.35K as of Q2 2026.
  • Regeneron Pharmaceuticals was a new Wedbush Fund Advisers position in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Wedbush Fund Advisers's portfolio in Q2 2026, its #99 holding.
  • 1,310 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Wedbush Fund Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.